0
Obstructive Lung Diseases |

Cardiovascular Safety of QVA149 in Patients With Moderate-to-Severe COPD: Pooled Analysis of FLIGHT1 and FLIGHT2 Clinical Studies

Robert Fogel, MD; Tim Ayers, MD; Donald Banerji, MD; Samopriyo Maitra, PhD; Agnes Annette Schubert-Tennigkeit, MD
Author and Funding Information

Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Healthcare Pvt Ltd, Hyderabad, India; Novartis Pharma AG, Basel, Switzerland


Chest. 2015;148(4_MeetingAbstracts):718A. doi:10.1378/chest.2277009
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD Posters IV

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: Monitoring cardiovascular safety is of importance when combining long-acting β2 agonists (LABA) and long-acting muscarinic antagonists (LAMA) (Tashkin et al. Respir Res. 2013; 14:49). Here, we analyze data from the FLIGHT1 and FLIGHT2 studies to assess the cardiovascular safety profile of QVA149 (a fixed-dose combination of LABA, indacaterol [IND] and LAMA, glycopyrronium [GLY]) versus its monocomponents (IND and GLY) and placebo.

METHODS: FLIGHT1 and FLIGHT2 were replicate, 12-week, multi-center, double-blind, parallel-group, placebo- and active-controlled studies that randomized patients with moderate‑to‑severe COPD (1:1:1:1) to twice daily QVA149 (IND/ GLY 27.5/12.5 μg), IND (27.5 μg), GLY (12.5 μg) or placebo. Cardiovascular safety of IND/GLY versus all treatment arms was assessed by recording all major adverse cardiovascular events (MACE) and/or cardiovascular deaths during the study.

RESULTS: Overall 2040 patients were included in the safety evaluation (IND/GLY, n=508; IND, n=511; GLY, n=513; placebo, n=508). The occurrence of MACE and/or cardiovascular deaths was <1% in all the active treatments and placebo treated group. No fatal MACE or CV death (IND/GLY, n=0; IND, n=1; GLY, n=1; placebo, n=1) was observed in the IND/GLY treatment group.

CONCLUSIONS: Overall major adverse cardiovascular events with IND/GLY were extremely low and comparable with its mono-components and placebo, reconfirming the safe use of the twice daily, fixed-dose combination, IND/GLY in patients with moderate‑to‑ severe COPD.

CLINICAL IMPLICATIONS: The safety findings support the use of IND/GLY as a maintenance bronchodilator treatment option in patients with moderate‑to‑severe COPD in the U.S.

DISCLOSURE: Robert Fogel: Employee: Employee of the study sponsor company (Novartis) and no other conflicts. Tim Ayers: Employee: Employee of the study sponsor company (Novartis) and no other conflicts. Samopriyo Maitra: Employee: Employee of the study sponsor company (Novartis) and no other conflicts. Agnes Annette Schubert-Tennigkeit: Employee: Employee of the study sponsor company (Novartis) and no other conflicts. Donald Banerji: Employee: Employee of the study sponsor company (Novartis) and no other conflicts.

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543